[Archyde.com]-Moderna, a major US biopharmacy company, plans to apply to the US authorities for an emergency use authorization (EUA) for a new coronavirus vaccine for children aged 6 months to 5 years by the end of this month. A spokeswoman said yesterday.
Clinical trials on children were conducted during the period when the Omicron strain became mainstream, and the preventive effect of 2-5 years of vaccination was about 38%, and that of 6 months to 2 years was 44%. According to the company, the effect on the Omicron strain was lower than that of the conventional strain even for adults who received two vaccinations, and it was about this level.
Last week, Pfizer and Biontech announced that they had confirmed a significant increase in antibody levels against the Omicron strain in a clinical trial of a third booster dose of the corona vaccine co-developed for ages 5-11.